StockWatch
·
Biotechnology: Pharmaceutical Preparations
Loan & DebtJun 23, 2026, 04:27 PM

Aditxt Amends Note Purchase Agreement, Increases Notes to $6.25M

AI Summary

Aditxt, Inc. entered into Amendment No.1 to its Note Purchase Agreement on June 22, 2026, increasing the aggregate original principal amount of senior secured convertible notes to $6,254,355.17. The company and its subsidiary, Ignite Proteomics LLC, issued and sold an additional $769,230.77 in principal amount of notes for a cash purchase price of $500,000.00. These additional notes, along with previously issued notes, are secured by substantially all assets of Ignite and a pledge of Aditxt's equity in Ignite.

Key Highlights

  • Amendment No.1 to Note Purchase Agreement dated June 22, 2026.
  • Aggregate original principal amount of senior secured convertible notes increased to $6,254,355.17.
  • Company issued and sold an additional $769,230.77 in principal amount of Notes.
  • Purchase price for additional notes was $500,000.00, paid in cash by investors.
  • Notes are secured by assets of Ignite Proteomics LLC and its subsidiaries.
  • Notes are further secured by a pledge of Aditxt's equity in Ignite Proteomics LLC.
  • Additional Notes were sold under Section 4(a)(2) and Rule 506(b) of Regulation D.